Mr. Cameron Groome reports

MICROBIX SCHEDULES RELEASE OF RESULTS FOR Q1 FISCAL 2026

Microbix Biosystems Inc. expects to file the financial statements, management disclosure and analysis, and results news release for its first quarter of fiscal 2026 ended Dec. 31, 2025 (Q1 2026) prior to the start of trading on Feb. 12, 2026. At 10 a.m. ET that day, Microbix intends to hold a webinar discussion of Q1 2026 results with its chief executive officer, chief financial officer and chief operating officer.

Investor and shareholders can participate in the webinar on-line, hosted by Adelaide Capital.

It will also be live streamed to YouTube.

Join through audio:   1-647-374-4685 (Canada)

Webinar ID:  851 0530 0389

A replay of the webinar will also be made available on Adelaide Capital's YouTube channel.

About Microbix Biosystems Inc.

Microbix Biosystems creates proprietary biological products for human health, with over 120 skilled employees and revenues of $18.6-million in its last reported fiscal year (2025). It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory-quality assessment products (QAPs) and reference materials (QUANTDx) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab accreditation organizations, diagnostics companies and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 and 13485 accredited, U.S. FDA (U.S. Food and Drug Administration) registered, Australian TGA (Therapeutic Goods Administration) registered, and Health Canada establishment licensed, and it provides IVDR-compliant (In Vitro Diagnostic Regulation) CE-marked (Conformite Europeenne) products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (for example, its DxTM for patient-sample collection). Microbix is traded on the Toronto Stock Exchange and OTCQX and is headquartered in Mississauga, Ont., Canada.

We seek Safe Harbor.